-
Top-ranked Alcaraz, Sabalenka win Miami openers
-
After Cuba beckons, Miami entrepreneurs are mostly reluctant to invest in the island
-
Peru's crowded presidential race zeroes in on organized crime
-
Taiwan's Lin to compete in first international event since Paris gender row
-
BTS takes over central Seoul for comeback concert
-
Jury signals tech titans on hook for social media addiction
-
Brumbies mark Slipper record in thriller against Chiefs
-
US jury finds Elon Musk misled Twitter shareholders
-
Gauff rallies to avance at Miami Open
-
WNBA, players union confirm agreement on 'groundbreaking' labor deal
-
Carrick 'baffled' by inconsistent penalty calls as Man Utd held
-
Trump says considering 'winding down' Iran war but rules out ceasefire
-
Trump mulls 'winding down' Iran war
-
Man Utd held by Bournemouth after Maguire sees red
-
Lens go top of Ligue 1 with handsome Angers win
-
Leipzig pummel Hoffenheim to climb to third
-
Quinn ousts 11th seed Ruud at rain-hit Miami Open
-
Rap group Kneecap says crisis-hit Cuba being 'strangled'
-
Anthony, Jackson nail US double at world indoors
-
Zarco seizes his moment as rain disrupts Brazil MotoGP practice
-
Chuck Norris, roundhouse-kicking action star, dead at 86
-
US newcomer Anthony crowned world indoor sprint king
-
Trump rules out Iran truce as more Marines head to Middle East
-
Costa Rican ex-security minister extradited to US for drug trafficking
-
Trump slams NATO 'cowards' as more Marines head to Middle East
-
Gulf's decades-long strategy of sporting investment rocked by Mideast war
-
Souped-up VPNs play 'cat and mouse' game with Iran censors
-
Attacked Russian tanker drifting toward Libya: Italian authorities
-
Coroner 'not satisfied' boxer Hatton intended to take own life
-
Stocks drop, as oil rises as Mideast war persists
-
Vanishing glacier on Germany's highest peak prompts ski lift demolition
-
Chuck Norris, roundhouse-kicking action star, dead at 86: family
-
Supreme leader says Iran dealt enemies 'dizzying blow'
-
Audi team principal Wheatley in shock exit after two races
-
Spurs boss Tudor hopes for 'nice surprises' in relegation fight
-
Arsenal must prove they are winners in League Cup final, says Arteta
-
Record-breaking heat wave grips western US
-
Liverpool showdown brings back 'beautiful memories' for PSG coach Luis Enrique
-
IRA bomb victims drop civil court claim against Gerry Adams
-
Ntamack returns for Toulouse to face France rival Jalibert
-
Trump calls NATO allies 'cowards' over Iran
-
French jihadist jailed for life for Islamic State crimes against Yazidis
-
Chuck Norris, action man who inspired endless memes, dead at 86: family
-
Action movie star Chuck Norris has died: family statement
-
England stars have 'last chance' to earn World Cup spots: Tuchel
-
League Cup final a 'big moment' for Man City, says Guardiola
-
Injured Ronaldo misses Portugal World Cup friendlies
-
Liverpool condemn 'cowardly' racist abuse of Konate
-
Far from war, global fuel frustrations mount
-
German auto exports to China plunged a third in 2025: study
RFK Jr panel votes against ingredient targeted by anti-vaxxers
A newly appointed US medical panel voted Thursday to oppose the use of a vaccine ingredient long targeted by Health Secretary Robert F. Kennedy Jr. over debunked claims it causes autism.
Thimerosal, a preservative that prevents bacterial and fungal contamination in multidose vials, has been extensively studied, with authorities including the World Health Organization finding no evidence of harm beyond minor injection-site reactions.
Though thimerosal is now rarely used in US vaccines, its inclusion on the Advisory Committee on Immunization Practices' agenda alarmed experts, who say the move has effectively embedded anti-vaccine talking points into national policy.
Kennedy -- who spent decades spreading vaccine misinformation before becoming President Donald Trump's top health official -- abruptly fired all 17 ACIP members earlier this month, accusing them of conflicts of interest.
Across three votes, his new handpicked panelists recommended that thimerosal be removed from influenza vaccines for children, pregnant women and finally all adults.
Cody Meissner, a professor of pediatrics at Dartmouth University and the lone voice of dissent, said: "The risk from influenza is so much greater than the nonexistent risk as far as we know from thimerosal," adding that he was worried about the decision's global impact.
Although 96 percent of US flu vaccines in the 2024-2025 season did not contain thimerosal, the preservative remains important globally, particularly in multidose vials that must be punctured repeatedly, raising the risk of contamination.
Thimerosal contains an artificial form of mercury called ethylmercury that is cleared from the body far more quickly than the form of the substance found in nature.
US manufacturers voluntarily removed it from most pediatric vaccines in 2001.
- 'Platform for anti-vaccine talking points' -
"The fact that it's being brought up again -- something that's already been adjudicated -- shows how the ACIP is becoming a platform for anti-vaccine talking points to come back to life long after most of us thought they'd been put to rest," Amesh Adalja, an infectious disease specialist at Johns Hopkins University, told AFP.
Ahead of the vote, Lyn Redwood, a nurse and former leader of the anti-vaccine group Children's Health Defense, which Kennedy once chaired, was invited to present arguments against thimerosal.
A previous version of her slideshow, which was posted online before the meeting, was removed without explanation after it was found to contain a fabricated citation, likely the result of an AI hallucination.
The Centers for Disease Control and Prevention had prepared a rebuttal to Redwood's presentation, but it was mysteriously removed from the meeting website.
Robert Malone, a new panel member known for spreading misinformation during the Covid-19 pandemic, including promoting the antiparastic drug ivermectin to treat the virus, later said the CDC document had not been approved by the Office of the Secretary.
Earlier in the meeting, the same panel voted to recommend a new antibody treatment against RSV, a common respiratory illness and the leading cause of infant hospitalization in the United States.
Clesrovimab, recently approved by the Food and Drug Administration, is administered as a single shot to newborns and young babies entering their first respiratory syncytial virus season.
Marketed as Enflonsia by Merck, it was shown in clinical trials to significantly reduce RSV infections and hospitalizations among infants.
X.M.Francisco--PC